Celconta Life Sciences Secures Tens of Millions in Pre-A Funding to Accelerate Solid Tumor CAR-T Cell Therapy Development

VCBeat learned第一时间获悉，近日，Shenzhen Xiankangda Life Science Co., Ltd. (hereinafter referred to as "Xiankangda Life") announced the completion of a Pre-A round of financing worth tens of millions of RMB. This round of financing was led by Guangdong Lianjing Investment Group Co., Ltd. (referred to as "Lianjing Investment"), and the funds raised will be mainly used to advance clinical research and IND applications for solid tumor CAR-T cell drugs.。

Yuan Dezong, Chairman of Lianjing Investment, and Mary Ma, Co-founder & CTO of Shenzhen Xiankangda Life Science Co., Ltd., at the signing ceremony

Shenzhen Xiankangda Life Science Co., Ltd. was founded in March 2020. It is a biopharmaceutical company focusing on the research and industrialization of cellular immunotherapy for solid tumors. The company possesses strong technological innovation capabilities and has developed three proprietary technology platforms: Trans-CAR, Boost-CAR, and R-Star. It has laid out 10 R&D pipelines, covering research directions such as CAR-T, CAR-NK, and iPSC-T, with over 40 patent applications filed cumulatively. Currently, Xiankangda Life's CAR-T products are undergoing clinical trials at multiple Class III, Grade A hospitals targeting Claudin18.2, GUCY2C, and other antigens. Preliminary data have shown controllable safety and promising clinical efficacy.

According to data released by the WHO, there were 19.758 million new cancer cases globally in 2021, including approximately 1.305 million new cases of hematological tumors, accounting for less than 10%. The remaining 90% were new cases of solid tumors. As CAR-T immunotherapy has made progress in the treatment of hematological tumors, its potential in addressing solid tumors has also become one of the most focused areas in the medical community. However, currently, solid tumors remain an obstacle that CAR-T immunotherapy has yet to overcome. To tackle the high incidence of solid tumors, Shenzhen Xiankangda Life Science Co., Ltd. has chosen to directly confront the highly challenging solid tumor CAR-T route, achieving breakthrough progress through technological innovation, accelerating the translational application of solid tumor CAR-T, and benefiting a large number of solid tumor patients.

Industry insiders pointed out that with future technological breakthroughs in the treatment of solid tumors and the advancement of treatment lines, the prospects for the cell therapy market will continue to be highly optimistic. According toFrost & Sullivan expects that by 2024, the market size of CAR-T cell therapy in China will grow to 5.3 billion yuan and further increase to 28.9 billion yuan by 2030, with a compound annual growth rate of 45.0% from 2022 to 2030.

Founder and Chairman of Xiankangda Group, Xie HaitaoRepresentation: Several CAR-T cell drugs have been approved for marketing both in China and abroad, showing very good efficacy. However, it is regrettable that these CAR-T cell drugs can only be used to treat hematological tumors and cannot yet be applied to solid tumors. The number of patients with solid tumors is nine times that of patients with hematological tumors, and more patients with solid tumors urgently need active treatment. After investing in Xiankangda Group, Lianjing Investment has now also invested in Shenzhen Xiankangda Life Science Co., Ltd. This is a great affirmation of the team and technology of Xiankangda Group. We will continue to spur ourselves on, redouble our efforts, and strive to get the cell drug from Shenzhen Xiankangda Life Science Co., Ltd. approved for marketing as soon as possible, achieving a breakthrough from zero, so that it can benefit solid tumor patients across China and even globally at an early date.

Chairman of Lianjing Investment, Yuan DezongCell and Gene Therapy (CGT) shows vast development potential in areas such as oncology, genetic disorders, and infectious diseases, and is set to become a major trend in modern healthcare. In recent years, China’s CGT industry has been growing rapidly, coupled with the swift expansion of the end-user market, presenting significant opportunities for growth. It is expected to maintain high-speed growth over the next 20 years. In the field of solid tumor treatment, Shenzhen Xiankangda Life Science Co., Ltd. boasts a strong team, having developed a proprietary technology platform and established a rich and forward-looking R&D pipeline. Lianjing Investment holds great confidence in the company, anticipating that Xiankangda Life will evolve into an internationally competitive biotechnology firm, and soon develop cellular drugs for solid tumors to benefit society.

Shenzhen Xiankangda Life Science Co., Ltd. is a subsidiary of Xiankangda Group, and it is a biopharmaceutical company that focuses on the research and industrialization of cellular immunotherapy for solid tumors. The company has laid out a rich and forward-looking R&D pipeline in the field of solid tumor treatment, including research directions such as CAR-T, CAR-NK, and iPSC-T, and has developed three technology platforms with independent intellectual property rights: Trans-CAR, Boost-CAR, and R-Star. Guided by clinical value, centered on patient needs, and driven by original innovation, the company is committed to continuously exploring the therapeutic effects of cell drugs in solid tumors and providing better treatment options for patients with solid tumors.

Lianjing Investment was founded by Yuan Dezong in 2011, mainly engaged in industrial investment, high-tech industry investment and its management, enterprise investment planning, consulting, etc. Under the leadership of Yuan Dezong, Lianjing Investment has invested in numerous strategic emerging industry enterprises.